These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15988069)

  • 21. The catalytic and GAF domains of the rod cGMP phosphodiesterase (PDE6) heterodimer are regulated by distinct regions of its inhibitory gamma subunit.
    Mou H; Cote RH
    J Biol Chem; 2001 Jul; 276(29):27527-34. PubMed ID: 11375400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
    Srivani P; Srinivas E; Raghu R; Sastry GN
    J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study.
    Oelke M; Hedlund P; Albrecht K; Ellinghaus P; Stief CG; Jonas U; Andersson KE; Uckert S
    Urology; 2006 May; 67(5):1111-6. PubMed ID: 16635522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6.
    Pissarnitski D
    Med Res Rev; 2006 May; 26(3):369-95. PubMed ID: 16388517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts.
    Keravis T; Thaseldar-Roumié R; Lugnier C
    Methods Mol Biol; 2005; 307():63-74. PubMed ID: 15988055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.
    Cahill KB; Quade JH; Carleton KL; Cote RH
    J Biol Chem; 2012 Nov; 287(49):41406-16. PubMed ID: 23033484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple zinc binding sites in retinal rod cGMP phosphodiesterase, PDE6alpha beta.
    He F; Seryshev AB; Cowan CW; Wensel TG
    J Biol Chem; 2000 Jul; 275(27):20572-7. PubMed ID: 10787404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time monitoring of phosphodiesterase inhibition in intact cells.
    Herget S; Lohse MJ; Nikolaev VO
    Cell Signal; 2008 Aug; 20(8):1423-31. PubMed ID: 18467075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determining the subunit structure of phosphodiesterases using gel filtration and sucrose density gradient centrifugation.
    Richter W
    Methods Mol Biol; 2005; 307():167-80. PubMed ID: 15988063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.
    Schröder S; Scheunemann M; Wenzel B; Brust P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.
    Corbin J; Francis S; Zoraghi R
    Int J Impot Res; 2006; 18(3):251-7. PubMed ID: 16281046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric Regulation of Rod Photoreceptor Phosphodiesterase 6 (PDE6) Elucidated by Chemical Cross-Linking and Quantitative Mass Spectrometry.
    Chu F; Hogan D; Gupta R; Gao XZ; Nguyen HT; Cote RH
    J Mol Biol; 2019 Sep; 431(19):3677-3689. PubMed ID: 31394113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
    Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
    Arnold NJ; Arnold R; Beer D; Bhalay G; Collingwood SP; Craig S; Devereux N; Dodds M; Dunstan AR; Fairhurst RA; Farr D; Fullerton JD; Glen A; Gomez S; Haberthuer S; Hatto JD; Howes C; Jones D; Keller TH; Leuenberger B; Moser HE; Muller I; Naef R; Nicklin PA; Sandham DA; Turner KL; Tweed MF; Watson SJ; Zurini M
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2376-9. PubMed ID: 17337182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
    Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
    Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
    Yang GF; Lu HT; Xiong Y; Zhan CG
    Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An HD-GYP cyclic di-guanosine monophosphate phosphodiesterase with a non-heme diiron-carboxylate active site.
    Miner KD; Klose KE; Kurtz DM
    Biochemistry; 2013 Aug; 52(32):5329-31. PubMed ID: 23883166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
    Corbin JD; Beasley A; Blount MA; Francis SH
    Biochem Biophys Res Commun; 2005 Sep; 334(3):930-8. PubMed ID: 16023993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.